RELB and hematologic disorder: While CD40 is known to activate non-canonical NF-κB signaling component RelB, which has been shown to control BCLXL expression in related hematological malignancies [25], the control of MCL1 by specific NF-κB subunits is less clear, particular in the context of lymphoma (Fig. 1A).